DLL4 Protein, Human, Recombinant

• Background:

  Delta-like protein 4 (DLL4, Delta4), a type I membrane-bound Notch ligand, is one of five known Notch ligands in mammals and interacts predominantly with Notch 1, which has a key role in vascular development. Recent studies yield substantial insights into the role of DLL4 in angiogenesis. DLL4 is induced by vascular endothelial growth factor (VEGF) and acts downstream of VEGF as a 'brake' on VEGF-induced vessel growth, forming an autoregulatory negative feedback loop inactivating VEGF. DLL4 is downstream of VEGF signaling and its activation triggers a negative feedback that restrains the effects of VEGF. Attenuation of DLL4/Notch signaling results in chaotic vascular network with excessive branching and sprouting. DLL4 is widely distributed in tissues other than vessels including many malignancies. Furthermore, the molecule is internalized on binding its receptor and often transported to the nucleus. In pathological conditions, such as cancer, DLL4 is up-regulated strongly in the tumour vasculature. Blockade of DLL4-mediated Notch signaling strikingly increases nonproductive angiogenesis, but significantly inhibits tumor growth in preclinical mouse models. In preclinical studies, blocking of DLL4/Notch signaling is associated with a paradoxical increase in tumor vessel density, yet causes marked growth inhibition due to functionally defective vasculature. Thus, DLL4 blockade holds promise as an additional strategy for angiogenesis-based cancer therapy.

• Synonyms:

  Delta-like 4 Protein, Human; hdelta2 Protein, Human

• Gene Name:

  Delta-like 4 (Drosophila)

• Expression System:

  HEK293 Cells

• Tag:

  No tag

• Field of Research:

  Cancer Drug TargetsNotch Pathway

• Endotoxin:

  < 1.0 EU per μg protein as determined by the LAL method.

• Purity:

  > 95 % as determined by SDS-PAGE.

• Activity:

  Measured by the ability of the immobilized protein to enhance BMP2-induced alkaline phosphatase activity in C3H10T1/2 mouse embryonic fibroblast cells. The EDfor this effect is typically 4-20 μg/mL in the presence of 500 ng/mL recombinant human BMP2.

• Form:

  Lyophilized

• Buffer:

  Lyophilized from sterile PBS, pH 7.4. Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hard copy of CoA.

• Function:

  Cell Therapy proteins

• Molecular Weight:

  The recombinant human DLL4 consists of 504 amino acids and predicts a molecular mass of 55 kDa.

• Storage Conditions:

  In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise. Stable for 1 year at -20°C or below from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and opening the cap. For long-term storage, aliquot and store at -20°C or below. Avoid repeated freeze-thaw cycles.

• Symbol:

  DLL4

• Species:

  Human

• Protein ID:

  NP_061947.1

• Overview:

  A DNA sequence encoding the human DLL4 (NP_061947.1) (Met1-Pro524) was expressed with five amino acids (DDDDK) at the C-terminus.

• AA Sequence:

  Met1-Pro524

• Protein ID Link:

  https://www.ncbi.nlm.nih.gov/protein/NP_061947.1